307 related articles for article (PubMed ID: 16796986)
1. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
2. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
3. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
Sulak P; Willis S; Kuehl T; Coffee A; Clark J
Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
[TBL] [Abstract][Full Text] [Related]
4. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
Coffee AL; Sulak PJ; Kuehl TJ
Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
[TBL] [Abstract][Full Text] [Related]
5. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
[TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
Sulak PJ; Kuehl TJ; Coffee A; Willis S
Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
[TBL] [Abstract][Full Text] [Related]
7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
8. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
10. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
12. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
14. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
15. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
17. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
18. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
Bruni Bresciani V
Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
[TBL] [Abstract][Full Text] [Related]
20. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
